Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
University of Miami
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05662306CT.gov C-Cog in Early Course Schizophrenia Study | — | Terminated | — | — | — |
NCT04203056CT.gov Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | — | Terminated | — | — | — |
NCT03345979CT.gov A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | — | Completed | — | — | — |
NCT02634320CT.gov A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia | — | Completed | — | — | — |
NCT02636842CT.gov A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder | — | Completed | — | — | — |
NCT02320032CT.gov An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia | — | Completed | — | — | — |
NCT01895452CT.gov An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | — | Completed | — | — | — |
NCT01626456CT.gov A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | — | Completed | — | — | — |
NCT01469039CT.gov A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia | — | Completed | — | — | — |
NCT01493726CT.gov A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aripiprazole Lauroxil (this asset) | University of Miami | Approved | BB · 66 |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Iloperidone | Vanda Pharmaceuticals | P4 | BBB |
| Raloxifene | Shanghai Mental Health Center | P4 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Aripiprazole Lauroxil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophreniform Disorder | — | P4 | B · 62 |
| Schizoaffective Depressive Disorder | — | P4 | B · 62 |
| Schizoaffective Disorder | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aripiprazole Lauroxil in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aripiprazole-lauroxil-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →